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Purpose of the article:To explore the strength of association between different maternal
and pregnancy characteristics and the occurrence of AIP.
Materials and Methods: Pubmed, Embase, CINAHL databases were searched. The
risk factors for AIP explored were: obesity, age >35 years, smoking before or during
pregnancy, placenta previa, prior cesarean section (CS), placenta previa and prior CS,
prior uterine surgery, abortion and uterine curettage, in vitro fertilization (IVF) pregnancy
and interval between a previous CS and a subsequent pregnancy. Random-effect head-to-
head meta-analyses were used to analyze the data.
Results: Forty-six were included in the systematic review. Maternal obesity (Odd ratio,
OR: 1.4, 95% CI 1.0-1.8), advanced maternal age (OR: 3.1, 95% CI 1.4-7.0) and parity
(OR: 2.5, 95% CI 1.7-3.6), but not smoking were associated with a higher risk of AIP. The
presence of placenta previa in women with at least a prior CS was associated with a higher
risk of AIP compared to controls, with an OR of 12.0, 95% CI 1.6-88.0). Furthermore,
the risk of AIP increased with the number of prior CS (OR of 2.6, 95% CI 1.6-4.4 and
5.4, 95% CI 1.7-17.4 for 2 and 3 prior CS respectively). Finally, IVF pregnancies were
associated with a high risk of AIP, with an OR of 2.8 (95% CI 1.2-6.8).
Conclusion: A prior CS and placenta previa are among the strongest risk factors for the
occurrence of AIP.
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Introduction
Abnormally Invasive Placenta (AIP) encompasses a heterogeneous group of anomalies
characterized by different degrees of invasion of chorionic villi through the myometrium
and uterine serosa [1].
Women affected by AIP require a tailored surgical management which is commonly
accomplished by fundal hysterotomy, followed by delivery of the fetus and subsequent
elective hysterectomy, although recent evidences suggest that an appropriate hemostatic
control can be achieved by conservative techniques aiming at preserving the uterus [2,3].
Such surgical approaches require an accurate prenatal identification of women affected by
AIP, which has been shown to reduce the burden of surgical complications associated with
these anomalies, such as massive hemorrhage, damage to adjacent organs and admission
to intensive care unit by allowing a pre-planned management of these conditions [4,5].
Prenatal diagnosis of AIP is usually accomplished by ultrasound, whereas fetal magnetic
resonance imaging (MRI) is commonly used to confirm the diagnosis and to delineate the
topography of placental invasion. Overall, prenatal imaging has been shown to reliably
identify these disorders and to predict their severity [6-9].
Recent studies suggested that prenatal diagnosis of AIP may improve when combining
imaging signs with maternal or pregnancy characteristics, such as parity, age or number
of prior cesarean section (CS) [10].
The aim of this systematic review was to explore the strength of association between
different maternal and pregnancy characteristics and the occurrence of AIP.
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Material and methods
Data sources
This review was performed according to an a-priori designed protocol and recommended
for systematic reviews and meta-analysis[11-13]. MEDLINE, Embase and CINAHL were
searched electronically on 23rd February 2017 and utilizing combinations of the relevant
medical subject heading (MeSH) terms, key words, and word variants for “abnormal
invasive placenta” “morbidly adherent placenta”, and “outcome” (Supplementary Table
1). The search and selection criteria were restricted to English language. Reference lists of
relevant articles and reviews were hand searched for additional reports. Prisma guidelines
were followed [14]. This study was registered with the PROSPERO database (Registration
number: CRD42018083510).
Main outcomes and measures
We aim to ascertain the strength of association between several maternal and pregnancy
risk factors and the occurrence of AIP. The risk factors for AIP explored were:
• Maternal obesity
• Maternal age >35 years
• Smoking before or during pregnancy
• Placenta previa
• Prior CS
• Placenta previa and prior CS
• Prior uterine surgery, including either CS or myomectomy
• Prior abortion
• Prior uterine curettage for abortion
• In vitro fertilization (IVF) pregnancy
• Interval between a previous CS and a subsequent pregnancy
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• Prior manual extraction of the placenta
For the assessment of the association between a prior CS and the occurrence of AIP, we
aimed to stratify the analysis according to the number (1, 2 and 3 previous CS) and type
(elective vs emergency) CS.
Eligibility criteria, study selection and data collection
Only studies reporting the prevalence of a given risk factor in women affected compared
to those not affected by AIP were considered eligible for the inclusion. Studies not
reporting a control group and those without a clear confirmation of AIP were excluded.
Studies published before 2000 were excluded, as we considered that improvements in
the diagnosis and definition of AIP make these less relevant. We planned to perform a
sensitivity analysis including only cases affected by placenta percreta.
Prospective and retrospective case-control studies, case reports and case series were
analysed. Opinions, cases series with less than four cases of AIP and case reports were
also excluded in order to avoid publication bias.
Two reviewers (AI, ML) independently extracted data. Inconsistencies were discussed
among the reviewers and consensus reached. For those articles in which targeted
information was not reported but the methodology was such that the information
might have been recorded initially, the authors were contacted requesting the data.
Histopathological findings and/or surgical notes were used as a gold standard.
Quality assessment of the included studies was performed using the Newcastle-Ottawa
Scale (NOS) for case-control studies; according to NOS, each study is judged on three
broad perspectives: the selection of the study groups; the comparability of the groups;
and the ascertainment outcome of interest [15]. Assessment of the selection of a study
includes the evaluation of the representativeness of the exposed cohort, selection of
the non-exposed cohort, ascertainment of exposure and the demonstration that outcome
of interest was not present at start of study. Assessment of the comparability of the
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study includes the evaluation of the comparability of cohorts based on the design or
analysis. Finally, the ascertainment of the outcome of interest includes the evaluation of
the type of the assessment of the outcome of interest, length and adequacy of follow-up.
According to NOS a study can be awarded a maximum of one star for each numbered
item within the Selection and Outcome categories. A maximum of two stars can be given
for Comparability [15].
Statistical analysis
We evaluated the association between 17 potential predictors and the presence of
abnormally invasive placenta (AIP) among pregnant women. Four out of 22 potential
predictors were continuous (maternal age, parity, number of previous cesarean sections
- CS, and BMI); 18 were categorical (maternal age >35 years, obesity, current smoking,
multiparity, diagnosis of placenta previa, diagnosis of placenta previa with previous CS,
previous CS, previous elective CS, previous emergency CS, previous uterine surgery,
previous abortion, previous curettage, in vitro fertilization - IVF, short interval (<23
months) between previous CS and subsequent pregnancy, manual extraction of the
placenta, uterine incision, endometrial ablation).
We first used random-effect head-to-head meta-analyses, expressing the results as
summary odds ratio (OR) or mean difference (and relative 95% Confidence Interval –
CI) for categorical or continuous predictors, respectively. When single study results were
reported as median and ranges, we used the method described by Hozo et al. to obtain
the corresponding means and standard deviations (SD), and when interquartile ranges
(IQR) rather than ranges were reported, they were divided by 1.35 to obtain the equivalent
SD [16,17]. In all meta-analyses, the statistical heterogeneity was quantified using the I2
metric.
Some of the comparisons involving the categorical predictors showed a marked imbalance
in the success rate between the groups being compared. Besides the computational issues,
in such cases the odds ratios may be of limited interest and sensitivity and specificity
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could be more informative. We thus calculated the overall sensitivity and specificity (and
related 95% CIs) for each comparison using the efficient-score method (corrected for
continuity) described by Newcombe [18]. Finally, we performed random-effect meta-
analyses of proportions to estimate the pooled rates of AIP by each categorical potential
predictor.
We were able to assess publication bias graphically, through funnel plots, and formally,
through Egger's regression asymmetry test, only in 10 out of 22 meta-analyses, because
the formal tests for funnel plot asymmetry cannot be used when the total number of
publications included for each outcome is <10 (the power is too low to distinguish chance
from real asymmetry) [17,19]. RevMan 5.3 (The Cochrane Collaboration, 2014) and Stata,
version 13.1 ( Stata Corp., College Station, TX, 2013) were used to analyse the data.
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Results
General characteristics
A total of 969 articles were identified. After screening the abstracts, 182 full text articles
were assessed with respect to their eligibility for inclusion (Supplemental Table 2) and
46 studies were included in the systematic review (Table 1, Figure 1) [10,20-64]. The
studies by Rac, Bowman and Wu [10,34,60], those by Weininger and Esh-Broder [37,47]
and those by Wong [53,57] were carried out in the same time periods and institutions;
however, because they looked at different potential predictors of AIP, were kept in the
systematic review (Table 1). These studies included 1085693 women (2219 AIP and
1083474 controls).
Quality assessment based on NOS guidelines is shown in Table 2. Most of the studies
were of high quality, and there was a low risk of bias and low concern regarding the
applicability of the studies. The small number of cases in some of the included studies,
different definitions of the risk factors analyzed, dissimilarity of the populations and lack
of stratification according to the severity of AIP represent their major weaknesses.
Synthesis of the results
Five studies (554106 pregnancies) explored the association between maternal obesity and
the occurrence of AIP, reported a higher risk of such disorders in obese vs non-obese
women with an OR of 1.4 (95% CI 1.0-1.8) (Table 3). Likewise, advanced maternal age
(OR: 3.1, 95% CI 1.4-7.0) and parity (OR: 2.5, 95% CI 1.7-3.6), but not smoking were
associated with a higher risk of AIP (Table 3).
Twenty-six (1.057.222 pregnancies) and thirty-three (656168 pregnancies) studies
respectively, reported the strength of association between placenta previa and CS and AIP
(Table 3). Overall, the presence of placenta previa was associated with a higher risk of
AIP compared to controls, with and OR of 11.0 (5% CI 4.7-25.8) and 4.7 (95% CI 3.0-7.2)
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(Table 3). More importantly, the risk of AIP increased with the number of prior CS (OR
of 2.6, 95% CI 1.6-4.4 and 5.4, 95% CI 1.7-17.4 for 2 and 3 prior CS respectively) (Table
3). When stratifying the analysis according to the type of AIP, there was no difference in
the prevalence of such disorders in women undergoing elective vs emergency CS. Finally,
there was no association between a short interval between the prior CS and a subsequent
pregnancy and the occurrence of AIP, although the two studies included in this analysis
differed as regard as the definition of such interval (Table 3).
The presence of placenta previa in women with at least a prior CS (twelve studies, 429.007
pregnancies) was associated with a higher risk of AIP compared to controls, with an OR
of 12.0, 95% CI 1.6-88.0) (Table 3).
Thirty-four studies explored the association between a prior uterine surgery, defined as
CS, myomectomy or any other procedure involving an hysterotomy and the occurrence
of AIP, reporting a higher risk of these disorders in women with a prior uterine surgery
(OR: 4.4, 95% CI 3.0-6.6) (Table 3).
A prior abortion was not associated with a higher risk of AIP, irrespective of the fact that
uterine curettage was performed. Finally, IVF pregnancies were associated with a high
risk of AIP, with an OR of 2.8 (95% CI 1.2-6.8).
Pooled proportions for the different risk factors explored in the present systematic review
in pregnancies affected compared to those not affected by AIP are reported in Table 4.
When considering only cases with a histopathological diagnosis of AIP, either maternal
age >35 years (OR: 3.9, 95% CI 2.6-5.9, I2: 0%), multiparity (OR: 3.5, 95% CI 2.4-5.3,
I2: 7.8%), placenta previa (OR: 14.5, 95% CI 5.4-39.3, I2: 63.5%), a prior CS (OR: 6.8,
95% CI 2.6-17.6, I2: 74.8%), prior uterine surgery (OR: 7.4, 95% CI 2.9-18.4, I2: 77.2%),
placenta previa and prior CS (OR: 10.6, 95% CI 2.2-52.6, I2: 63.9%), IVF pregnancy
(OR: 11.6, 95% CI 6.2-21.5, I2: 0%) were associated with the occurrence of AIP, while
prior uterine curettage for abortion (OR: 2.5, 95% CI 0.9-6.6, I2: 51.9%), smoking (OR:
0.92, 95% CI 0.2-4.2, I2: 32.9%) and manual extraction of the placenta (OR: 0.8, 95% CI
0.03-17.3, I2: 0%) did not show any degree of association with such anomalies.
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Discussion
Main findings
The findings from this systematic review showed that advanced maternal age, obesity,
parity, prior CS, placenta previa and IVF are associated with a significant high risk of AIP.
A prior CS and placenta previa are among the strongest risk factors for the occurrence of
AIP, with such risk increasing with the number of prior CS or when placenta previa and
CS co-exist.
Strengths and limitations
The small number of cases in some of the included studies, their retrospective non-
randomized design, different definitions of the risk factors analyzed among the included
studies and dissimilarity of the populations (due to various inclusion criteria) represent the
major limitations of this systematic review. Assessment of the potential publication bias
was also problematic because of the nature of the outcome evaluated (outcome rates, with
the left-side limited to a value of zero), which limits the reliability of funnel plots, and
because of the scarce number of individual studies, which strongly limits the reliability
of formal tests. Not all the included studies were case-control series reporting matched
populations and it might be entirely possible that the presence and degree of association
between some of the risk factors explored and AIP might have been affected by other
several maternal or pregnancy characteristics which were not balanced between cases
affected and not affected by AIP. Furthermore, we could not completely ascertain the
possible association between some of the explored potential predictors, such as the type
of CS, uterine incision and interval between CS and following pregnancy, and AIP in
view of the very small number of included studies and the different cut-offs adopted in
the included studies [65].
Despite these limitations, the present review represents the most comprehensive published
estimate of the investigated outcomes in twin pregnancies affected by discordant growth.
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Implications for clinical practice
Accurate prediction of AIP is fundamental in order to improve the surgical outcome of
these anomalies [5]. Recent studiessuggested that predictive models integrating maternal
characteristics and imaging signs can improve the diagnostic accuracy of prenatal imaging
in detecting AIP [10,66].
In the present systematic review, the presence of both placenta previa and a prior CS
was not unsurprisingly associated with the highest risk of AIP. Furthermore, the risk of
AIP increased with increasing the number of prior CS. These findings suggest that every
woman presenting with placenta previa and at least one prior CS should be considered to
be potentially affected by AIP and referred to centers with high expertise in diagnosis and
management in order to rule out these anomalies.
Fetal MRI should be considered because it may add useful information on the depth and
topography of placental invasion which may modify surgical management. Serial follow-
up scans should be also arranged because signs of AIP can be evident only later on in
gestation. Despite this, it should be stressed that about 10% of women affected by the
most severe types of AIP remained undiagnosed until birth, thus highlighting the need for
developing more accurate predictive models for detecting these anomalies.
In the present review, we found a significant association between IVF pregnancies and
AIP. Although commonly reported, such association is difficult to explain. It might be
entirely possible that the reported association between AIP and IVF might have been
affected by the presence of other risk factors such as advanced maternal age or BMI.
Alternatively, it might be hypothesized that IVF per se increase the risk of AIP. Although
controlled ovarian stimulation allows to retrieve a considerable number of oocytes thus
increasing the success rate of IVF cycles, it has also been shown to alter endometrial
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receptivity and structure by inducing abnormal levels of estradiol [67-69], which affect
placental implantation.
Prenatal diagnosis of AIP is commonly performed during the second and third trimester
of pregnancy, while there is no robust data on first trimester diagnosis, with most of the
studies including only cases affected by these anomalies. Despite this, it has still to be
ascertained when to scan women at risk of AIP. One of the most relevant issues when
trying to diagnose AIP is which sub-set of women should be referred for an early detailed
assessment in order to rule out AIP. The major risk factors for AIP are placenta previa and
previous caesarean section. However, AIP can occur even in women with no classical risk
factors for these conditions. In a recent large cohort study, Bailit et al. reported that 18%
of women with AIP were nulliparous and that 37% had no prior CS, thus challenging the
theory that AIP can occur almost exclusively in multiparous women [65].
Despite this, it is authors’ collective opinion that every woman with at least one prior CS
should be scanned early in pregnancy (between 5 and 9 weeks of gestation) in order to
assess the gestational sac position, relationship with prior CS and anterior uterine wall
and to stratify the risk of AIP [70-72].
Further large studies are need in order to build reliable predictive models for AIP tailored
upon maternal characteristics, ultrasound and MRI signs observed in order to improve the
diagnostic accuracy of prenatal imaging in detecting AIP.JU
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CE
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Table 1. General characteristics of the included studies
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Author Year Country Study
design
Period
analysed
Inclusion criteria Pregnancies
(n)
AIP
(n)
Controls
(n)
Millischer[20]2017 France Retrospective2009-2012 Placenta previa + prior CS
and US suspicion of AIP
20 8 12
Pilloni[21] 2016 Italy Prospective2011-2014Placenta previa (26 weeks of gestation) 314 37 277
Thiravit[22] 2016 Thailand Retrospective2005-2014 Women with ultrasound
suspicion of AIP
21 12 9
Collins
[23]
2015 United
Kingdom/
United States
Prospective2012-2014 Clinical and/or ultrasound
suspicion of AIP
89 42 47
Lyell[24] 2015 United States Retrospective2009-2010 AIP and matched controls 736 37 699
Miller[25] 2015 United States Retrospective2008-2013 AIP and matched controls 125 25 100
Parra-
Herran[26]
2015 Canada Retrospective2002-2015 Women undergoing
postpartum hysterectomy
61 44 17
Thurn[27] 2015 Denmark,
Finland, Iceland,
Norway,
and Sweden
Prospective2009-2012 Women affected by AIP
vs general population
605567 205 605
362
Alchalabi[28]2014 Jordan Retrospective2003-2012 Women who had CS for
AIP or placenta previa
81 23 58
Bour[29] 2014 France Retrospective2006-2012 Clinical and/or US suspicion of AIP 32 16 16
Rac[10] 2014 United States Retrospective1997-2011 Placenta previa/low lying + >1 CS 184 54 130
Zhou[30] 2014 China Retrospective2011-2013 Women with prior CS 68 12 56
Noda[31] 2014 Japan/
United States
Retrospective2011-2013 Women with suspicion of AIP 28 7 21
Asıcıoglu[32]2014 Turkey Retrospective2005-2010 placenta previa 364 46 318
Laban[33] 2014 Egypt Retrospective2012-2013 AIP and matched controls 76 26 50
Bowman[34]2013 United States Retrospective1999-2002 Women affected or non-
affected by AIP with a prior CS
2749 196 2553
Cali[35] 2013 Italy Prospective2004-2012 Placenta previa and
prior uterine surgery
187 41 146
Ueno[36] 2013 Japan Retrospective2009-2013 Women undergoing MRI
for the suspicion of AIP
65 15 50
Weiniger[37]2013 Israel Prospective2002-2011 92 52 40
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Placenta previa and/or at least
one CS suspected of AIP on US
Eshkoli[38] 2013 Israel Retrospective1988-2011 AIP and matched controls 34869 139 34.730
Kamara[39] 2013 Australia Prospective1993-2008 Placenta previa + prior CS 167 65 102
Klar[40] 2013 Germany Retrospective2000-2007 AIP and unmatched controls 483 161 322
Upson[41] 2013 Ireland Retrospective2005-2010 All deliveries 403602 357 403
245
Fitzpatrick[42]2012 United KingdomRetrospective2010-2011 All women with AIP vs
all women with no AIP
390 134 256
Hannon[43] 2012 United KingdomRetrospective NS Cases of post-partum hysterectomy 16 12 4
Chantraine[44]2012 Argentina-
Germany-
Belgium
Retrospective NS Women with placenta increta 22 13 9
Lim[45] 2011 United States Retrospective2009-2010Clinical and/or US risk factors for AIP 13 9 4
Sadashivaiah[46]2011 United KingdomRetrospective2004-2008 Women undergoing
interventional radiology for AIP
13 4 9
Esh-
Broder[47]
2011 Israel Retrospective2004-2009 All deliveries 25235 42 25193
Derman[48] 2011 United States Retrospective NS Women with ultrasound
suspicion of AIP
17 4 13
El
Behery[49]
2010 Egypt Prospective2007-2009 Clinical risk factors for AIP 35 7 28
Hasegawa[50]2009 Japan Retrospective2000-2007 Placenta previa 127 5 122
Morita[51] 2009 Japan Retrospective 2008 Women undergoing MRI
for the suspicion of AIP
7 3 4
Dwyer[52] 2008 United States Retrospective2001-2016 Clinical or imaging suspicion of AIP 32 15 17
Wong[53] 2008 New Zeland Prospective2004-2006 Clinical risk factors for AIP 66 9 57
Tantbirojn[54]2008 United States Retrospective2002-2007 Cases of post-partum hysterectomy 49 38 11
Mok[55] 2008 United Kingdom prospective2002-2007 Women with ultrasound
suspicion of AIP undergoing
interventional radiology
13 5 8
Japaraj[56] 2007 Malaysia Prospective2002-2005 Placenta previa + prior CS 20 7 13
Wong[57] 2007 New Zeland retrospective2004-2005 Clinical and/or ultrasound
suspicion of AIP
36 5 31
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Bencaiova[58]2007 Switzerland retrospective1999-2003 AIP and matched controls 8839 31 8808
Warshak[59]2006 United States Retrospective2000-2005 US diagnosis or suspicion of AIP 28 12 16
Wu[60] 2005 United States Retrospective1982-2002 AIP and matched controls 450 111 339
Usta[61] 2005 Lebanon Retrospective1983-2003 Placenta previa 347 22 325
Gielchinsk[62]2004 Israel Retrospective1990-2000 AIP and matched controls 620 310 310
Chou[63] 2000 Taiwan Retrospective1994-1998Women with persistent placenta previa 80 14 66
Twickler[64]2000 United States Retrospective NS Women with placenta
previa and prior CS
20 9 11
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Table 2. Quality assessment of the included studies according to Newcastle-Ottawa
Scale (NOS) a study can be awarded a maximum of one star for each numbered item
within the Selection and Outcome categories. A maximum of two stars can be given for
Comparability.
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Author Year Selection Comparability Outcome
Millischer[20]
2017
  
Pilloni[21]
2016
  
Thiravit[22]
2016
  
Collins[23]
2015
  
Lyell[24]
2015
  
Miller[25]
2015
  
Parra-Herran[26]
2015
  
Thurn[27]
2015
  
Alchalabi[28]
2014
  
Bour[29]
2014
  
Rac[10]
2014
  
Zhou[30]
2014
  
Noda[31]
2014
  
Asıcıoglu[32]
2014
  
Laban[33]
2014
  
Bowman[34]
2013
  
Calì[35]
2013
  
Ueno[36]
2013
  
Weiniger[37]
2013
  
Eshkoli[38]
2013
  
Kamara[39]
2013
  
Klar[40]
2013
  
Upson[41]
2013
  
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Fitzpatrick[42]
2012
  
Hannon[43]
2012
  
Chantraine[44]
2012
  
Lim[45]
2011
  
Sadashivaiah[46]
2011
  
Esh-Broder[47]
2011
  
Derman[48]
2011
  
El Behery[49]
2010
  
Hasegawa[50]
2009
  
Morita[51]
2009
  
Dwyer[52]
2008
  
Wong[53]
2008
  
Tantbirojn[54]
2008
  
Mok[55]
2008
  
Japaraj[56]
2007
  
Wong[57]
2007
  
Bencaiova [58]
2007
  
Warshak[59]
2006
  
Wu[60]
2005
  
Usta[61]
2005
  
Gielchinsky[62]
2004
  
Chou[63]
2000
  
Twickler[64]
2000
  
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Table 3. Results of the head-to-head meta-analyses comparing the risk of abnormally
invasive placenta (AIP) for each categorical potential predictor (see also online figures
S1-S32).
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Predictors N. studies
(sample)
References Total
women
(n/N vs
n/N)*
OR
(95% CI)
p I2,% Sensitivity
(95% CI)
Specificity
(95% CI)
Obesity 5
(554,106)
24,27,36,38,4274/66,469
vs
442/487,637
1.37
(1.04-1.81)
0.02 0 14.3
(11.4-17.7)
88.0
(87.8-88.1)
Maternal age
>35 years
17
(1,055,206)
20,24,27,28,36,38,41,42,45,46,50,54,55,58-61499/138 1 8
vs
653/916,688
3.13
(1.40-6.97)
0.005 96 48.7
(38.0-59.6)
77.0
(67.3-84.6)
Current smoking 11
(1,048,980)
24,27,34,36,38-42,45,61209/130,136
vs
1130/918,844
1.13
(0.88-1.47)
0.34 38 8.60
(3.40-20.0)
90.8
(83.3-95.2)
Multiparity 20 (1,022,675) 23-28,34,39,
41,42,45,46,51,54,55,58,59,61,62
621/46,403
vs
938/976,362
2.49
(1.71-3. 1)
<0.001 76 40.5
(27.9-54.5)
79.1
(65.9-88.1)
Placenta previa 24
(1,057,222)
22,23,25-27,
29-31,34,37,
38,41-43,45,
48,49,51,52,
54,57-59,62
644/5256
vs
1050/1,051,966
11.0
(4.71-25.8)
<0.001 96 69.0
(51.9-82.2)
84.7
(64.5-94.4)
Placenta previa
+previous CS
12
(429,007)
23,27,29,32,
35,45,46,50-52,59,61
200/912 vs
131/428,095
12.0
(1.64-88.0)
0.01 97 87.2
(67.7-95.9)
54.1
(14.5-89.1)
≥1 previous CS 33
(656,168)
22-27,28,29,
31-36,38,40,
42-46,49-51,
54-59,61-63
925/80,458
vs
737/575,710
4.66
(3.02-7.18)
<0.001 82 85.1
(71.7-92.8)
53.5
(39.4-67.0)
Previous
elective CS
3
(606,098)
27,32,39 169/43,982
vs
337/649,742
3.73
(0.50-27.7)
0.20 98 87.2
(66.7-95.9)
54.1
(14.5-89.1)
Previous
emergency CS
3
(606,098)
27,32,39 127/62,219
vs
189/543,879
1.17
(0.21-6.65)
0.9 97 40.2
(34.7-45.8)
89.8
(89.7-89.8)
Previous
uterine surgery
34
(1,057,363)
21-29,31-33,
5,36,38,40-46,49-52,54,
55,57-59,61-63
893/116,082
vs
976/941,281
4.42
(2.96-6.59)
<0.001 82 84.4
(70.7-92.4)
55.4
(41.9-68.1)
Previous
abortion
6
(36,111)
26,28,38-40,60179/3019
vs
364/33,092
1.36
(0.84-2.20)
0.21 62 25.6
(6.88-61.5)
72.4
(51.4-59.4-82.4)
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Previous
curettage
16
(10,886)
22,23,25,26,32,35,37,40,44,45,49,54,56-58,60232/1099
vs
412/9787
1.87
(0.96-3.64)
0.06 82 31.5
(19.0-47.3)
78.8
(66.5-87.4)
IVF 7
(488,897)
23,27,36,38,40,42,4751/14,402
vs
598/474,495
2.80
(1.16-6.76)
0.02 82 8.84
(5.02-15.1)
96.5
(92.2-98.4)
Short interval**
between
previous CS
and subsequent
pregnancy
2
(820)
24,42 62/195 vs
81/625
1.81
(0.72-4.58)
0.21 68 43.4
(35.1-51.9)
80.4
(77.2-83.3)
CS = Caesarean section; IVF = In vitro fertilization; OR = Odds Ratio; CI = Confidence Interval; * The first “n/
N” refers to e.g. the number of obese women with AIP (n) / the total number of obese women without AIP (N); the
second “n/N” refers to the number of non-obese women with AIP (n) / the total number of non-obese women without
AIP. ** <23 months.
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Table 4. Proportion meta-analysis: pooled rates of abnormally invasive placenta (AIP) in women
with (A) and without (B) each categorical potential predictor.
Pooled % of AIP
(95% CI)
Pooled % of AIP
(95% CI)
Predictors A B
Maternal age >35 years 16.9 (11.9-22.4) 0.8 (0.4-1.3)
Obesity 3.3 (0.0-12.3) 5.5 (3.2-8.2)
Current smoking 0.8 (0.0-2.3) 6.1 (4.9-6.5)
Multiparity 27.7 (17.4-39.0) 5.5 (4.4-6.7)
Diagnosis of placenta previa 50.9 (37.2-64.5) 1.7 (0.9-2.8)
Placenta previa+previous CS 40.9 (27.2-55.3) 5.7 (0.5-14.3)
≥1 previous CS 35.2 (29.2-41.4) 5.0 (2.5-8.1)
Previous elective CS 16.8 (0.1-50.7) 5.2 (0.0-19.9)
Previous emergency CS 10.3 (0.0-40.3) 16.0 (0.0-52.2)
Previous myomectomy 25.5 (0.0-71.1) 43.3 (29.2-58.0)
Previous uterine surgery 30.7 (26.6-34.9) 1.3 (0.6-2.2)
Previous abortion 32.9 (5.2-69.6) 26.1 (5.6-54.6)
Previous curettage 38.0 (21.6-55.6) 32.8 (16.0-52.2)
IVF 3.5 (0.4-8.57) 9.7 (6.8-12.9)
Short interval* between
previous CS and subsequent
pregnancy
28.6 (22.5-35.2) 8.8 (6.7-11.2)
Manual extraction of the
placenta
15.8 (0.0-93.8) 31.9 (9.30-59.8)
Uterine incision 100.0 (20.6-100.0) 75.5 (67.8-81.9)
Endometrial ablation 100.0 (20.7-100.0) 46.6 (36.5-56.9)
CS = Cesarean section; IVF = In vitro fertilization; CI = Confidence Interval; * <23 month
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Figure legend
Figure 1. Systematic review flowchart
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